返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Hosts SuperPath™ Hip Arthroplasty and Fast Recovery Seminar

[2017-10-10] 

Suzhou, China – On September 17, MicroPort® Orthopedics hosted SuperPath™ Minimally Invasive Hip Arthroplasty and Fast Recovery Seminar in the First Affiliated Hospital of Soochow University. The symposium focused on the advantages and surgical tips of SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™"). Around 100 experts from Jiangsu, Beijing, Guangxi, Jiangxi, Shandong and Henan provinces attended the event. Meanwhile over 200 people watched online by allinmd.cn.
 
During the symposium, Professor Yaozeng Xu, Joint Surgery Director of the First Affiliated Hospital of Soochow University, performed bilateral total hip replacement in one-stage procedure to an arthritis patient. Meanwhile, Director Jun Zhou explained the key steps of the surgery to attendees based on his personal clinical experience. The surgery achieved successful result with complete soft tissue and little blood loss, which fully demonstrated the advantages of SuperPath™.
 
In the discussion session, Professor Yaozeng Xu introduced the possible difficulties and coping tactics of using SuperPath™ technique in total and hemi hip arthroplasty based on surgical videos. Director Rongqun Li analyzed the clinical efficacy of SuperPath™ total hip arthroplasty through large amount of follow-up data. Dr. Lianfang Zhang shared the clinical experience in performing a bilateral total hip arthroplasty with SuperPath™ technique. Director Jun Zhou presented on the latest advancement in fast recovery philosophy and analyzed the advantages and disadvantages of modular femoral stem through detailed literatures.
 
By live surgeries, surgical observations, and instrument operating, the experts in attendance had better understanding in the advantages and surgical skills of SuperPath™ technique. One expert said, as a minimally invasive hip arthroplasty technique, SuperPath™ follows the "Fast Recovery" philosophy, which is definitely worth being introduced to local hospitals to benefit more patients.
 
As the world's first total hip arthroplasty minimally invasive technique that facilitates a faster return to function for patients, SuperPath™ technique not only offers patients with small incision, but also provides added advantages like preservation of the external rotators, decreased operative time, decreased intra-operative blood loss, increased post-operative stability, as well as decreased post-operative recovery time and pain. SuperPath™ technique has been used in 25 provinces and cities of China, and an increasingly more surgeons have mastered the technique, allowing more patients to get a faster return to function with reduced complications.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:Canadian Orthopedic Expert Professor Paul Beaule Visits MicroPort® Orthopedics for Academic Exchange
[Next]:First Post-market Implantation of Castor® Successfully Completed